Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FLGT NASDAQ:INNV NASDAQ:PSNL NASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLGTFulgent Genetics$18.08+0.2%$20.16$14.57▼$25.11$556.06M1.03284,347 shs247,071 shsINNVInnovAge$4.30-1.6%$4.01$2.60▼$6.69$586.48M0.5150,526 shs40,992 shsPSNLPersonalis$6.51+0.5%$5.80$2.22▼$7.79$580.70M1.951.16 million shs961 shsXGNExagen$7.26+3.6%$6.81$1.78▼$7.95$154.06M1.58144,849 shs641,257 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLGTFulgent Genetics+0.50%-7.26%-10.51%+1.51%-22.22%INNVInnovAge-3.20%+0.71%+13.10%+53.82%-29.26%PSNLPersonalis+1.09%-6.36%+4.01%+103.13%+188.00%XGNExagen+2.57%+2.57%-7.12%+59.91%+250.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFLGTFulgent Genetics4.0682 of 5 stars3.31.00.04.12.63.30.6INNVInnovAge0.8876 of 5 stars1.82.00.00.01.61.70.6PSNLPersonalis3.3555 of 5 stars2.51.00.04.21.92.50.6XGNExagen3.1554 of 5 stars1.52.00.04.52.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLGTFulgent Genetics 2.50Moderate Buy$24.0032.38% UpsideINNVInnovAge 1.50Reduce$5.0018.20% UpsidePSNLPersonalis 3.00Buy$7.6718.31% UpsideXGNExagen 3.00Buy$7.504.46% UpsideCurrent Analyst Ratings BreakdownLatest XGN, FLGT, INNV, and PSNL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025XGNExagenUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025PSNLPersonalisGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.005/15/2025XGNExagenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.005/13/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/7/2025XGNExagenBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/7/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.005/6/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$16.00 ➝ $23.005/5/2025FLGTFulgent GeneticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$24.00 ➝ $25.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLGTFulgent Genetics$292.45M1.89N/AN/A$36.92 per share0.49INNVInnovAge$763.85M0.75N/AN/A$2.04 per share2.07PSNLPersonalis$84.61M6.76N/AN/A$2.87 per share2.26XGNExagen$55.64M2.75N/AN/A$0.54 per share13.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLGTFulgent Genetics-$42.71M-$1.33N/AN/AN/A-13.94%-2.19%-2.02%8/1/2025 (Estimated)INNVInnovAge-$21.34M-$0.23N/A70.50N/A-3.75%-11.91%-5.85%9/9/2025 (Estimated)PSNLPersonalis-$81.28M-$1.29N/AN/AN/A-98.10%-48.78%-34.70%8/6/2025 (Estimated)XGNExagen-$15.11M-$0.84N/AN/AN/A-27.34%-133.69%-34.87%7/29/2025 (Estimated)Latest XGN, FLGT, INNV, and PSNL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025PSNLPersonalis-$0.25N/AN/AN/A$20.12 millionN/A8/4/2025Q2 2025XGNExagen-$0.18N/AN/AN/A$16.25 millionN/A8/1/2025Q2 2025FLGTFulgent Genetics-$0.23N/AN/AN/A$76.21 millionN/A5/12/2025Q1 2025XGNExagen-$0.20-$0.20N/A-$0.20$14.55 million$15.50 million5/6/2025Q3 2025INNVInnovAge-$0.02-$0.08-$0.06-$0.08$214.09 million$218.14 million5/6/2025Q1 2025PSNLPersonalis-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million5/2/2025Q1 2025FLGTFulgent Genetics-$0.18$0.04+$0.22-$0.37$71.26 million$73.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFLGTFulgent GeneticsN/AN/AN/AN/AN/AINNVInnovAgeN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLGTFulgent GeneticsN/A6.326.32INNVInnovAge0.040.780.78PSNLPersonalisN/A6.916.74XGNExagen2.872.322.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLGTFulgent Genetics48.06%INNVInnovAge12.26%PSNLPersonalis61.91%XGNExagen75.25%Insider OwnershipCompanyInsider OwnershipFLGTFulgent Genetics31.76%INNVInnovAge1.40%PSNLPersonalis3.80%XGNExagen12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFLGTFulgent Genetics1,31330.44 million20.78 millionOptionableINNVInnovAge2,350135.01 million133.12 millionOptionablePSNLPersonalis40088.32 million84.97 millionOptionableXGNExagen22021.30 million18.62 millionOptionableXGN, FLGT, INNV, and PSNL HeadlinesRecent News About These CompaniesExagen (NASDAQ:XGN) versus Varex Imaging (NASDAQ:VREX) Head to Head ReviewJuly 18 at 2:59 AM | americanbankingnews.comExagen Inc. Appoints Chas McKhann to Board of DirectorsJuly 17 at 4:05 PM | globenewswire.comExagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025July 15 at 4:32 PM | globenewswire.comExagen Insider Ups Holding During YearJune 29, 2025 | finance.yahoo.com2025-06-23 | Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics | NDAQ:XGN | Press Release - StockhouseJune 24, 2025 | stockhouse.comMichael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune DiagnosticsJune 23, 2025 | globenewswire.comExagen announces resale of up to 1.15M sharesJune 20, 2025 | msn.comExagen Inc. Holds 2025 Annual Stockholder MeetingJune 11, 2025 | tipranks.comExagen Inc. (NASDAQ:XGN) Q1 2025 Earnings Call TranscriptMay 11, 2025 | insidermonkey.comExagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional SharesMay 9, 2025 | finance.yahoo.comExagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional SharesMay 9, 2025 | globenewswire.comExagen Inc. Prices Public Offering of Common StockMay 8, 2025 | globenewswire.comKeyBanc maintains Exagen stock at Sector WeightMay 7, 2025 | investing.comKeyBanc maintains Exagen stock at Sector WeightMay 7, 2025 | investing.comExagen Inc. Announces Proposed Public Offering of Common StockMay 7, 2025 | globenewswire.comEarnings call transcript: Exagen Inc. Q1 2025 revenue beats forecasts, stock dipsMay 6, 2025 | uk.investing.comExagen Inc. Reports Record Revenue Amid Strategic GrowthMay 5, 2025 | tipranks.comExagen Inc. Earnings Call Highlights Record GrowthMay 5, 2025 | tipranks.comExagen Inc. (XGN) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comExagen Inc. (XGN) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXGN, FLGT, INNV, and PSNL Company DescriptionsFulgent Genetics NASDAQ:FLGT$18.08 +0.04 (+0.19%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.InnovAge NASDAQ:INNV$4.30 -0.07 (-1.60%) As of 09:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in its homes and communities. The company manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. It also offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. The company serves participants in the United States; and operates PACE centers in Colorado, California, New Mexico, Pennsylvania, Florida, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.Personalis NASDAQ:PSNL$6.51 +0.03 (+0.49%) As of 09:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Exagen NASDAQ:XGN$7.26 +0.26 (+3.64%) As of 09:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
